Latest News and Press Releases

New class action filing lets Wildermuth Fund investors seek recovery for alleged securities fraud violations. Lead plaintiff deadline: December 29, 2025.

Grindr Inc. shareholders are encouraged to contact BFA Law about its investigation into the take-private transaction.

On May 27, 2025, Savara revealed the FDA refused to file its MOLBREEVI BLA due to insufficient CMC data, causing shares to fall $0.90, or 31.69%, to $1.94.

Allegedly, defendants hid unauthorized FDA design changes to DexCom’s G6 and G7, making them less reliable and exposing users to health risks.

The complaint alleges Fiserv misled investors about its 2025 initiatives, later admitting its guidance was based on assumptions that were unrealistic.

The complaint alleges Savara misled investors about its MOLBREEVI BLA readiness; the FDA’s refusal to file caused shares to drop 31.7% to $1.94.

The lawsuit alleges CarMax overstated growth tied to tariffs, later missed estimates, reported declines, and investors suffered losses.

The complaint alleges KBR misled investors about TRANSCOM’s concerns over HomeSafe’s contract performance, causing losses when the truth emerged.

Defendants allegedly hid Avantor’s weakening competitive position and lost accounts, leading to weak Q3 results, a $785M charge, and a 23% stock drop.

Allegedly, defendants misled investors about the completeness of Savara’s MOLBREEVI BLA, leading to an FDA refusal and a 31.7% stock drop on May 27, 2025.